HAVCR2 and cancer: In mouse pre-clinical models and cancer patients, TIGIT expression on tumor-infiltrating CD8+ T cells often links with augmented expression of other inhibitory receptors like PD-1, LAG-3, TIM-3, and decreased expression of DNAM-1 [65, 67, 68].